Review
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 21, 2015; 21(3): 742-758
Published online Jan 21, 2015. doi: 10.3748/wjg.v21.i3.742
Use of mesenchymal stem cells to treat liver fibrosis: Current situation and future prospects
Silvia Berardis, Prenali Dwisthi Sattwika, Mustapha Najimi, Etienne Marc Sokal
Silvia Berardis, Prenali Dwisthi Sattwika, Mustapha Najimi, Etienne Marc Sokal, Laboratory of Pediatric Hepatology and Cell Therapy, Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires St Luc, Université Catholique de Louvain, 1200 Brussels, Belgium
Author contributions: Berardis S, Dwisthi Sattwika P, Najimi M and Sokal EM wrote the paper.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Silvia Berardis, MD, Laboratory of Pediatric Hepatology and Cell Therapy, Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires St Luc, Université Catholique de Louvain, Avenue Hippocrate 10, 1200 Brussels, Belgium. silvia.berardis@uclouvain.be
Telephone: +32-2-7645285 Fax: +32-2-7648909
Received: July 29, 2014
Peer-review started: July 31, 2014
First decision: August 15, 2014
Revised: September 5, 2014
Accepted: November 18, 2014
Article in press: November 19, 2014
Published online: January 21, 2015
Processing time: 174 Days and 23.7 Hours
Abstract

Progressive liver fibrosis is a major health issue for which no effective treatment is available, leading to cirrhosis and orthotopic liver transplantation. However, organ shortage is a reality. Hence, there is an urgent need to find alternative therapeutic strategies. Cell-based therapy using mesenchymal stem cells (MSCs) may represent an attractive therapeutic option, based on their immunomodulatory properties, their potential to differentiate into hepatocytes, allowing the replacement of damaged hepatocytes, their potential to promote residual hepatocytes regeneration and their capacity to inhibit hepatic stellate cell activation or induce their apoptosis, particularly via paracrine mechanisms. The current review will highlight recent findings regarding the input of MSC-based therapy for the treatment of liver fibrosis, from in vitro studies to pre-clinical and clinical trials. Several studies have shown the ability of MSCs to reduce liver fibrosis and improve liver function. However, despite these promising results, some limitations need to be considered. Future prospects will also be discussed in this review.

Keywords: Liver fibrosis; Cirrhosis; Mesenchymal stem cells; Cell therapy; Hepatic stellate cells

Core tip: Liver fibrosis is a major public health issue for which no treatment is available. Cell therapy and, in particular, mesenchymal stem cells (MSCs), represent a promising strategy, based mainly on their immunomodulatory properties and differentiation capacity. In the current review, we discuss the rationale to propose cell therapy and, in particular, MSCs to treat liver fibrosis, overview of the current knowledge in this field and highlight future prospects.